Hubbry Logo
NimesulideNimesulideMain
Open search
Nimesulide
Community hub
Nimesulide
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Nimesulide
Nimesulide
Nimesulide
View on Wikipedia
from Wikipedia

Nimesulide
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth, rectal, topical
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding>97.5%
MetabolismHepatic
Elimination half-life1.8–4.7h
ExcretionRenal (50%), fecal (29%)
Identifiers
  • N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.052.194 Edit this at Wikidata
Chemical and physical data
FormulaC13H12N2O5S
Molar mass308.31 g·mol−1
3D model (JSmol)
  • [O-][N+](=O)c2cc(Oc1ccccc1)c(cc2)NS(=O)(=O)C
  • InChI=1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3 checkY
  • Key:HYWYRSMBCFDLJT-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) with pain medication and fever reducing properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis, and primary dysmenorrhoea in adolescents and adults above 12 years old.

Side effects may include liver problems.[1] It has a multifactorial mode of action and is characterized by a fast onset of action. It works by blocking the production of prostaglandins (a chemical associated with pain), thereby relieving pain and inflammation.

Medical uses

[edit]

It may be used for pain, including period pains. Nimesulide is not recommended long-term, as for chronic conditions such as arthritis. This is due to its association with an increased risk of liver toxicity, including liver failure.[2] Despite its risk of hepatotoxicity, a 2012 evaluation by the European Medicines Agency (EMA) concluded that the overall benefit/risk profile of nimesulide is favourable and in line with that of the other NSAIDs such as diclofenac, ibuprofen, and naproxen provided that the duration of use is limited to 15 days and the dose does not exceed 200 mg/day.[3]

Children

[edit]

Less than 10 days of nimesulide does not appear to increase the risk of hypothermia, gastrointestinal bleeding, epigastric pain, vomiting, diarrhea, or transient, asymptomatic elevation of liver enzymes compared to ketoprofen, paracetamol, mefenamic acid, aspirin, or ibuprofen in children. However, data does not speak to populations less than 6 months old.[4]

Pregnancy and lactation

[edit]

Women should use the drug with caution during lactation and nimesulide is contraindicated during pregnancy, and research suggest that it is also contraindicated in lactating women.[5]

Available forms

[edit]
100mg Nimesulide pills

Nimesulide is available in a variety of forms: tablets, powder for dissolution in water, suppositories, mouth dissolving tablets, and topical gel.

Contraindications

[edit]

It should be avoided by children under 12 and people with liver problems.

Side effects

[edit]

Due to concerns about the risk of liver toxicity, nimesulide has been withdrawn from market in several countries (Mexico,[6] Spain, Finland, Belgium, and Ireland).[7] Liver problems have resulted in both deaths and the need for transplantation.[1] The frequency of nimesulide-induced liver injury is estimated at around 1 in 50,000 patients, severe injury has occurred in as little as three days after starting the medication.[1][8] Shorter (≤ 15 days) duration of therapy does not prevent serious nimesulide hepatotoxicity.[9]

Continuous use of nimesulide (more than 15 days) may cause the following side effects:[medical citation needed]

  • Diarrhea
  • Vomiting
  • Skin rash
  • Itchiness
  • Dizziness
  • Bitterness in mouth

Pharmacology

[edit]

Pharmacodynamics

[edit]

Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID), acting specifically as a relatively selective cyclooxygenase-2 inhibitor.[3][10] However, the pharmacological profile of nimesulide is peculiar, and additional, unknown/yet-to-be-identified mechanisms appear to also be involved.[3][10] One pathway that has been implicated in its actions is the ecto-5'-nucleotidase (e-5′NT/CD73)/adenosine A2A receptor pathway.[3]

Pharmacokinetics

[edit]

Nimesulide is absorbed rapidly following oral administration.[11]

Nimesulide undergoes extensive biotransformation, mainly to 4-hydroxynimesulide (which also appears to be biologically active).[11]

Food, sex, and advanced age have negligible effects on nimesulide pharmacokinetics.[11]

Moderate chronic kidney disease does not necessitate dosage adjustment, while in patients with severe chronic kidney disease or liver disease, nimesulide is contraindicated.[12]

Nimesulide has a relatively rapid onset of action, with meaningful reductions in pain and inflammation observed within 15 minutes from drug intake.[13][14]

The therapeutic effects of nimesulide are the result of its complex mode of action, which targets a number of key mediators of the inflammatory process such as: COX-2 mediated prostaglandins, free radicals, proteolytic enzymes, and histamine.[13] Clinical evidence is available to support a particularly good profile in terms of gastrointestinal tolerability.[15]

History

[edit]

Nimesulide was launched in Italy for the first time as Aulin and Mesulid in 1985 and is available in more than 50 countries worldwide, including among others Portugal, Greece, Russia, Thailand, and Brazil.[16] Nimesulide has never been filed for Food and Drug Administration (FDA) evaluation in the United States, where it is not marketed.

Society and culture

[edit]

Brand names

[edit]

Nimesulide is available throughout the world as original product with the following trademarks: Sulide, Nimalox, Mesulid (Novartis, Brazil, Boehringer Ingelheim, Greece, Italy, Hungary), Coxtal (Sanofi, China, Bulgaria), Sintalgin (Abbott, Brazil), Eskaflam (GSK, Brazil, Mexico), Octaprin, Nimside (Teva, Pakistan), Nise (Russia, Venezuela, Vietnam, Ukraine), Nilsid (Egypt); Aulin (Bulgaria, Czech Republic, Italy, Romania, Poland), Ainex, Drexel, Donulide, Edrigyl, Enetra, Heugan, Mesulid, Minapon, NeRelid, Nexen, Nidolon, Nilden (Mexico); Emsulide, Nimed, Nimedex, Nimesil (Czech Republic, Moldova, Latvia, Lithuania, Kazakhstan, Georgia, Poland, Russia, Ukraine), Nimulid (Trinidad & Tobago), Nimutab, Nimdase, Nimopen-MP Nise, Nimuwin, Nisulid, Nodard Plus, Nicip, Nimcap, Nic-P, Nic-Spas, Nimupain (India); Mesulid, Novolid, Relmex (Ecuador); Remisid (Ukraine); Coxulid, Emulid, Frenag, Fuzo, Motival, Nimeksil, Nimelid, Nîmes, Nimesdin, Romasulid, Sulidin, Suljel, Thermo Sulidin (Turkey), Xilox (Hungary); Modact-IR (Pakistan); and ad Sulidene and Zolan for veterinary use. Many generic and copy-products also exist (Lusemin, Medicox, Nidol, Nimalox, Nimesil, Nimotas, Nimulid, Nizer, Sorini, Ventor, Vionim, Neolide, Willgo among others), new-aid, Nexulide (Syria), Nims, Nice, Nimulide (Nepal)

India

[edit]

Several reports have been made of nimesulide's adverse drug reactions in India.[17][18][19][20] On 12 February 2011, The Indian Express reported that the Union Ministry of Health and Family Welfare had finally decided to suspend the pediatric use of the analgesic suspension.[21] From 10 March 2011 onward, nimesulide formulations are not indicated for human use in children below 12 years of age.[22]

On 13 September 2011, the Madras High Court revoked a suspension on manufacture and sale of paediatric drugs nimesulide and phenylpropanolamine (PPA).[23]

On 30 December 2024, the Central government banned the manufacture, sale and distribution of nimesulide and its formulations for animal use.[24] This was in response to studies conducted at the Indian Veterinary Research Institute (IVRI) at Izatnagar, Bareilly, showing nimesulide causing lethal kidney problems in wild vultures, especially Himalayan griffon vultures, which consume the drug through carcasses of treated livestock.[25][26]

EMA confirms the positive benefit/risk ratio

[edit]

On September 21, 2007 the EMA released a press release on their review on the liver-related safety of nimesulide. The EMA has concluded that the benefits of these medicines outweigh their risks, but that there is a need to limit the duration of use to ensure that the risk of patients developing liver problems is kept to a minimum. Therefore, the EMA has limited the use of systemic formulations (tablets, solutions, suppositories) of nimesulide to 15 days.[27]

Irish Medicines Board

[edit]

The Irish Medicines Board has decided to suspend Nimesulide from the Irish market and refer it to the EU Committee for Human Medicinal Products (CHMP) for a review of its benefit/risk profile. The decision is due to the reporting of six cases of potentially-related liver failures to the IMB by the National Liver Transplant Unit, St. Vincent's University Hospital. These cases occurred in the period from 1999 to 2006.[28]

Bribes

[edit]

In May 2008, Italy's leading daily paper Corriere della Sera and other media outlets[citation needed] reported that a top-ranking official at Italy's medicines agency AIFA had been filmed by police while accepting bribes from employees of pharmaceutical companies.[29][30] The money allegedly was being paid to ensure that certain drugs would be spared scrutiny from the drugs watchdog. The investigation had started in 2005 following suspicions that some AIFA drug tests had been faked. Eight arrests were made. Nimesulide can be bought carrying a prescription from a physician that is kept as a receipt at the chemist shop, nominally allowing strong control over selling.

The original manufacturer of nimesulide is Helsinn Healthcare SA, Switzerland, which acquired the rights for the drug in 1976. After the patent protection terminated in 2015,[31] a number of other companies started production and marketing of Nimesulide.

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Nimesulide

View on Grokipedia
from Grokipedia

Nimesulide is a sulfonanilide class (NSAID) that selectively inhibits (COX-2) over cyclooxygenase-1 (COX-1). It is indicated for short-term symptomatic relief of acute pain, , and primary dysmenorrhoea in adolescents and adults over 12 years of age. Compared to traditional NSAIDs, nimesulide demonstrates reduced gastrointestinal adverse effects due to its COX-2 selectivity. Despite its efficacy in , nimesulide has been linked to a dose-dependent risk of , with meta-analyses indicating approximately a twofold increased odds of relative to other NSAIDs. This association has prompted regulatory actions worldwide, including non-approval in the United States and withdrawal or severe restrictions in countries such as , , and the , while remaining available with limitations in select European nations like and . Empirical data from studies underscore rare but severe outcomes, including hepatocellular and , particularly in elderly patients or with prolonged use exceeding recommended durations. These risks have fueled ongoing debates on its benefit-risk profile, prioritizing safer alternatives for routine analgesia where possible.

Chemical and Pharmacological Properties

Mechanism of Action

Nimesulide exerts its primary , , and effects through selective inhibition of (COX-2), an enzyme upregulated at sites of inflammation. This preferential COX-2 blockade reduces the synthesis of pro-inflammatory , such as PGE2, while exhibiting weaker inhibition of COX-1, the constitutive isoform responsible for gastroprotective prostaglandin production in the . assays demonstrate nimesulide's for COX-2 inhibition at approximately 90 μM, confirming its potency against this isoform compared to non-selective NSAIDs. Beyond COX inhibition, nimesulide modulates additional pathways contributing to its rapid action in acute conditions. It scavenges free radicals and inhibits the release of from activated neutrophils, mitigating at inflammatory sites. Nimesulide also suppresses release and reduces the production of pro-inflammatory cytokines, such as those induced by , through interference with cellular signaling cascades independent of COX pathways. Animal studies corroborate nimesulide's enhanced anti-inflammatory potency relative to traditional NSAIDs like or ibuprofen at equimolar doses, attributed to its multi-mechanistic profile including partial COX-1 engagement for optimal efficacy. In models of , nimesulide demonstrated superior suppression of paw and compared to non-selective inhibitors, linking its effects to combined COX-2 selectivity and antioxidant properties. These findings from preclinical models highlight causal contributions from radical scavenging and cytokine modulation to its therapeutic profile.

Pharmacokinetics

Nimesulide is rapidly and extensively absorbed from the following of 100 mg doses in tablet, granule, or suspension form, with mean peak plasma concentrations (C_max) of 2.86 to 6.50 mg/L achieved within 1.22 to 2.75 hours, regardless of formulation. The onset of the analgesic effect typically occurs within 15-30 minutes after ingestion of tablets, due to rapid absorption preceding peak levels, though dissolution time in conventional tablets may introduce slight variability compared to faster formulations like mouth-dissolving tablets. The duration of the analgesic effect lasts 6–12 hours. does not substantially alter the rate or extent of absorption. Steady-state plasma levels are attained within 24 to 48 hours upon twice-daily dosing, consistent with its low hepatic extraction ratio of approximately 0.1. The drug is highly bound to plasma proteins, exceeding 97.5%. Nimesulide undergoes extensive hepatic , primarily via the enzyme to the pharmacologically 4'-hydroxynimesulide, with contributions from and possibly CYP1A2. The terminal elimination of the parent compound ranges from 1.8 to 4.7 hours, while the exhibits a slightly prolonged of about 3 to 4 hours. Minor metabolites are also formed, but the 4'-hydroxy derivative predominates. Elimination of unchanged nimesulide is negligible in and (less than 1-3% of the dose), with metabolites accounting for the majority of —approximately 50% via the renal route and the balance through biliary into . This profile, dominated by hepatic metabolism and biliary elimination, implies potential accumulation and altered clearance in hepatic impairment, supporting restricted use or dose adjustments in such patients, whereas minimal renal involvement of the parent drug reduces the need for modifications in renal dysfunction.

Clinical Applications

Indications

Nimesulide is primarily indicated for the short-term treatment of mild to moderate acute and fever, including intense muscle or joint pain, sprains, cramps, musculoskeletal and post-operative , where its selective inhibition of provides rapid symptomatic relief. Clinical studies have demonstrated its effectiveness in reducing intensity in acute settings, such as dental surgery and , with onset of action supporting its use in conditions requiring prompt analgesia. For , nimesulide is approved for the of and , particularly in acute exacerbations, but not as a first-line or long-term option due to hepatotoxicity concerns limiting duration to typically no more than 15 days. Double-blind trials have shown significant improvements in scores and joint function compared to in osteoarthritis patients, confirming its role in managing flare-ups rather than chronic progression. Primary represents another key indication, with evidence from controlled studies indicating superior pain reduction over baseline in adolescents and adults during menstrual cycles, aligning with its preference for acute inflammatory pain. Regulatory assessments emphasize its second-line status for these uses in jurisdictions where authorized, excluding chronic inflammatory arthritides like , where safer long-term alternatives are preferred based on broader safety profiles.

Dosage Forms and Administration

Nimesulide is formulated in various suitable for oral, rectal, and topical administration, including 100 mg tablets, granules or powder for oral suspension, suppositories, capsules, and topical gels. Dispersible or effervescent tablets and oral suspensions provide options for easier ingestion, particularly in cases requiring rapid dissolution. Nimesulide is not indicated for children under 12 years. For adults and children above 12 years, the usual dose is 50 to 100 mg twice daily, administered orally with a glass of water after meals to reduce gastrointestinal upset. The maximum daily dose is generally limited to 200 mg (in exceptional cases and for short periods under medical guidance), with treatment restricted to acute conditions and the shortest effective duration, generally not exceeding 15 days. In jurisdictions where nimesulide remains approved, such as , regulatory bodies like the Drugs Technical Advisory Board (DTAB) under the Central Drugs Standard Control Organization (CDSCO) endorse 100 mg dosing while prohibiting oral immediate-release formulations exceeding this strength to mitigate risks. Administration should follow evidence-based protocols, with discontinuation advised if symptoms persist beyond the initial treatment period without clinical improvement.

Use in Special Populations

Nimesulide is generally contraindicated or advised against in children under 12 years of age in many regions due to insufficient long-term safety data, reports of elevated hepatotoxicity risk in pediatric populations, and regulatory restrictions. However, in jurisdictions where permitted, formulations such as oral drops (e.g., 50 mg/mL suspension, approximately 2.5 mg per drop) may be used under strict medical supervision with weight-based dosing of about 1 drop per kg body weight twice daily (equivalent to 5 mg/kg/day). Systematic reviews indicate that while short-term efficacy for pain relief may exist, the potential for serious liver injury outweighs benefits, with calls from medical bodies to discontinue use in children where alternatives are available. In pregnancy, nimesulide is classified as category C by some regulatory assessments, with use restricted and generally avoided, particularly after 20 weeks gestation due to risks of fetal kidney problems and premature closure of the ductus arteriosus akin to other NSAIDs. Early pregnancy exposure has been associated with increased odds of congenital urinary tract anomalies in observational studies. It is contraindicated in the third trimester. For lactation, nimesulide passes into breast milk in low amounts, classified as low risk by some databases, but guidelines recommend avoidance due to potential infant exposure and lack of extensive safety data. In elderly patients, no specific dosage adjustment is required, but caution is advised owing to heightened susceptibility to adverse effects, including gastrointestinal and renal complications common with NSAIDs; regular monitoring of renal and hepatic function is recommended. For renally impaired patients, no adjustment is needed for mild to moderate cases (creatinine clearance >30 mL/min), but it is contraindicated in severe impairment. In hepatically impaired individuals, nimesulide is avoided due to its association with drug-induced liver injury, with dose reduction or discontinuation advised if pre-existing liver dysfunction is present.

Efficacy and Clinical Evidence

Key Clinical Trials

A double-blind randomized controlled trial published in 1992 compared nimesulide (100 mg twice daily) to ketoprofen (100 mg twice daily) in patients with dental pain and inflammation, finding nimesulide provided more rapid and effective relief of pain at rest and upon mastication, as well as reduced swelling, compared to ketoprofen. In a 2014 double-blind, randomized, parallel-group study of 188 patients experiencing moderate to severe pain after surgical extraction of impacted third molars, once-daily nimesulide (100 mg) was compared to ibuprofen (600 mg); both regimens achieved effective 24-hour pain relief, but significantly more patients in the nimesulide group reported overall effective treatment (82% vs. 73%; P = 0.013), with similar reductions in visual analog scale (VAS) pain scores. For osteoarthritis, two double-blind multicenter studies conducted in 1994 evaluated nimesulide (100 mg twice daily for 15 days) versus in patients with knee ; both trials demonstrated statistically significant improvements in spontaneous (via VAS), on movement, and functional capacity (e.g., walking and rising from a ) with nimesulide compared to baseline and (P < 0.01). A 2005 double-blind randomized trial of 120 patients with of the hip or knee compared nimesulide (100 mg twice daily for 4 weeks) to (50 mg three times daily); nimesulide showed superior relief across parameters including VAS scores for at rest, on movement, and night (P < 0.05), alongside improvements in joint tenderness and mobility. Meta-analyses of randomized controlled trials have confirmed nimesulide's rapid in acute models, with (NNT) values for at least 50% relief typically ranging from 3 to 4, comparable to other non-steroidal drugs in short-term use. These trials collectively highlight nimesulide's in acute postoperative and chronic osteoarthritic , emphasizing faster VAS score reductions with standard dosing of 100 mg twice daily.

Comparative Effectiveness vs. Other NSAIDs

Nimesulide demonstrates a rapid onset of analgesia, with significant achieved in about 70% of patients within 15 minutes in observational studies of acute . This faster time-to-relief positions it advantageously for acute inflammatory flares compared to , where animal model comparisons using radiant heat and writhing tests indicated quicker onset and prolonged duration with nimesulide. Head-to-head further support superiority in speed over selective COX-2 inhibitors like celecoxib and , with nimesulide providing more rapid symptomatic in knee osteoarthritis patients as measured by visual analog scales. In osteoarthritis treatment, nimesulide exhibits equivalent efficacy to in controlling symptoms, including pain intensity and functional impairment, with both drugs yielding comparable reductions in Lequesne index scores over 8 weeks in randomized trials. Patient-reported outcomes, such as joint swelling resolution, favored nimesulide slightly, with 80% of treated patients showing no swelling at 24 weeks versus 66.7% for . Meta-analyses of short-term (2-week) use confirm nimesulide's noninferiority to in osteoarthritis pain and stiffness relief, based on pooled data from multiple double-blind studies. Comparative trials against naproxen in hip and knee osteoarthritis report similar overall potency, with nimesulide-beta-cyclodextrin achieving equivalent WOMAC pain subscale improvements over 2 weeks in multicenter, double-blind designs. Real-world pharmacoepidemiological from post-marketing aligns with findings, showing no inferior symptom control outcomes relative to standard NSAIDs in routine clinical use for acute and . These metrics underscore nimesulide's competitive profile in potency and patient-centered relief speed without of diminished effectiveness in broader populations.

Long-Term Data and Real-World Outcomes

In , where nimesulide remains widely prescribed for acute and , annual usage exceeds millions of prescriptions, contributing to a market value of over Rs 497 as of 2025. Post-marketing surveillance studies, including those evaluating hundreds of patients with fever and inflammatory conditions, have documented effective symptom resolution without observed or disproportionate adverse liver events relative to exposure volume. Observational cohort analyses from Indian clinical practice, such as a multicenter of 1,873 adults across 528 centers treated for , 66.8% achieving complete and tolerability profiles with minimal adverse effects, aligning with outcomes for analgesics under routine monitoring. Similarly, prospective multicentric cohorts assessing fixed-dose combinations for trauma-related and musculoskeletal confirm sustained in real-world sustained short-to-medium-term use, with low discontinuation rates due to safety issues. Pharmacoepidemiological evaluations in the , drawing from large-scale Indian data, affirm nimesulide's role in resource-constrained environments for targeted , where its rapid onset supports without elevated signals compared to other non-steroidal anti-inflammatory drugs in population-level surveillance. These findings underscore effective integration into pathways, provided usage adheres to short-duration guidelines and periodic liver function assessments.

Safety and Adverse Effects

Common Side Effects

The most frequently reported adverse effects of nimesulide are mild and primarily involve the , including , dyspepsia, and abdominal discomfort, with an incidence of gastrointestinal events around 9.2% in large clinical trials of patients with osteoarticular disorders. These effects occur at a lower rate than with non-selective NSAIDs due to nimesulide's preferential inhibition of (COX-2) over COX-1, which reduces disruption to protective gastric prostaglandins. Central nervous system effects such as and are also common, typically affecting 2–5% of users based on post-marketing surveillance and tolerability studies, alongside occasional . Dermatological reactions like or pruritus are reported infrequently, often resolving without intervention. These side effects are generally dose-dependent and transient, abating upon discontinuation of the drug in the majority of cases, distinguishing them from rarer severe events. Overall tolerability remains favorable in short-term use, with total rates around 11% in controlled settings.

Hepatotoxicity Risks and Incidence

Nimesulide-associated manifests as idiosyncratic , presenting with signs including anorexia, nausea, abdominal pain, fatigue, dark urine, and jaundice; patients experiencing these symptoms should seek immediate medical attention for liver function tests. The estimated incidence is 1 to 9 cases per 100,000 exposed patients annually, though rates vary by population and surveillance method. Hospitalization for (DILI) linked to nimesulide has been quantified at approximately 33 cases per 100,000 patient-years of use, exceeding the NSAID class average of 22 per 100,000 patient-years. The injury pattern is predominantly hepatocellular or cytolytic, observed in 41% of documented cases, with mixed or cholestatic features in the remainder. Over 90% of cases resolve upon drug discontinuation, though progression to occurs in a minority, with fatalities reported in less than 5% of severe instances. A 2019 systematic review and of 25 observational studies, including five eligible for pooled estimation, reported nimesulide use linked to with an (OR) of 7.02 (95% CI 4.28–11.50), reflecting a significantly elevated relative to non-exposure. Adjusted reporting odds ratios (RORs) from pharmacovigilance databases indicate nimesulide's signal strength aligns closely with that of , another NSAID with established hepatotoxic potential, without definitive evidence of inherently superior causality beyond class effects. Italian case-control studies from post-marketing surveillance corroborate this, estimating an adjusted OR of 2.10 (95% CI 1.28–3.47) for acute serious , with escalating by cumulative exposure duration exceeding 30 days. Elevated odds are associated with modifiable factors such as overdose, concurrent alcohol consumption, and underlying liver conditions, alongside non-modifiable elements like advanced age and sex predominance in case series. Post-marketing data from high-use regions like and highlight these patterns, with Italian registries documenting disproportionate reports prompting enhanced monitoring, while Indian captures similar idiosyncratic events amid widespread availability.

Other Serious Adverse Events

Nimesulide exhibits a low risk of cardiovascular thrombotic events attributable to its preferential rather than highly selective COX-2 inhibition, distinguishing it from agents like that demonstrated elevated risks in clinical trials. Pharmacodynamic analyses indicate no significant , with post-marketing surveillance failing to identify a consistent signal for or beyond background rates in NSAID users. Renal effects are primarily limited to transient elevations in serum or reductions in , observed in susceptible populations such as dehydrated individuals or those with underlying impairment. Acute and rare cases of acute renal failure have been documented in pharmacovigilance reports, but controlled studies involving repeated dosing up to 800 mg daily showed no clinically meaningful in healthy volunteers. Caution is advised in patients with pre-existing renal disease, as nimesulide may exacerbate functional decline, though incidence remains below 1% in broad cohorts. Severe hypersensitivity reactions, including Stevens-Johnson syndrome and , occur infrequently, with databases documenting fewer than 250 attributed cases globally amid millions of prescriptions. These events typically manifest within days of initiation and are more probable in patients with prior NSAID sensitivities, but population-level reporting rates suggest an incidence under 1 per million exposures.

Contraindications and Precautions

Absolute Contraindications

Nimesulide is absolutely contraindicated in patients with known hypersensitivity to the drug, its excipients, or sulfonanilides, as this can precipitate severe allergic reactions including anaphylaxis. This includes history of hypersensitivity to aspirin or other NSAIDs manifesting as bronchospasm, rhinitis, urticaria, or angioedema. Use is strictly prohibited in individuals with active peptic ulcer disease or a history of recurrent peptic ulceration or gastrointestinal hemorrhage (at least two episodes), due to the heightened risk of serious upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs. Prior hepatic reactions to nimesulide also constitute an absolute contraindication. The drug must not be administered to patients with severe heart failure (New York Heart Association class IV), severe renal insufficiency, or severe coagulation disorders, as nonsteroidal anti-inflammatory drugs like nimesulide can exacerbate fluid retention, precipitate acute decompensation, impair renal function, or increase bleeding risks. Nimesulide is contraindicated in those with severe hepatic impairment, active liver disease, or a history of drug-induced liver injury, reflecting its established association with idiosyncratic hepatotoxicity that can lead to acute liver failure. Concurrent administration with other known hepatotoxic agents is prohibited to prevent additive or synergistic liver damage, particularly in light of nimesulide's dose-dependent and idiosyncratic hepatic risks documented in pharmacovigilance data. Nimesulide is contraindicated during pregnancy, particularly in the third trimester, due to risks of fetal complications such as premature closure of the ductus arteriosus associated with NSAID use. In jurisdictions where regulatory restrictions apply, and as advised by many common bulletins and guidelines due to elevated liver risks, nimesulide is contraindicated for pediatric patients under 12 years of age, supported by empirical evidence of disproportionate hepatotoxicity incidence and severity in this population from post-marketing surveillance and clinical reports.

Relative Precautions and Monitoring

Patients at increased risk for hepatotoxicity, such as those with a history of liver disease, chronic alcohol consumption, or conditions predisposing to hepatic impairment, require cautious use of nimesulide with close monitoring. Treatment should be initiated only after assessing baseline liver function tests (LFTs), including ALT, AST, and bilirubin levels, and discontinued immediately if elevations exceed three times the upper limit of normal (ULN), even in the absence of symptoms, to prevent progression to severe injury. For prolonged therapy beyond 7 days, periodic LFT monitoring every 1-2 weeks is recommended, alongside patient education on symptoms like jaundice, fatigue, or abdominal pain. Renal precautions include ensuring adequate hydration to mitigate risks of acute kidney injury, particularly in patients with dehydration, advanced age, or pre-existing mild renal impairment, as nimesulide can impair renal prostaglandin synthesis leading to reduced glomerular filtration. Obese patients or those with comorbidities like hypertension warrant vigilance, as NSAID use may exacerbate fluid retention or unmask underlying renal vulnerabilities, though direct obesity-specific data for nimesulide remain limited. Caution is also required in patients with cardiac impairment, with monitoring of renal and cardiac function to avoid worsening. Elderly patients exhibit increased sensitivity to NSAID adverse effects, including gastrointestinal bleeding or perforation, renal impairment, cardiac events, and hepatotoxicity; prolonged use should be avoided without careful monitoring. Caution is advised in patients with coagulation disorders or bleeding tendencies, such as hemophilia, due to potential inhibition of platelet aggregation. For gastrointestinal risks, treatment should be interrupted if signs of ulceration or bleeding occur, with added caution in patients with a history of gastrointestinal disorders. In patients with asthma, nimesulide may precipitate bronchospasm, necessitating caution. Use should be discontinued if ocular visual disturbances arise. During lactation, nimesulide requires caution as low levels may be excreted in breast milk; benefits to the mother must outweigh potential risks to the infant. Drug interactions necessitate monitoring when nimesulide is co-administered with CYP2C9 inhibitors like fluconazole, which can elevate nimesulide plasma levels by reducing its metabolism, potentially heightening hepatotoxicity risk; dose reduction or alternative therapy may be advised. Similarly, caution applies with other hepatotoxic agents or drugs affecting renal function, such as diuretics, where combined use has shown potential for decreased efficacy or additive toxicity in clinical reports. Overall, short-term use (≤7 days) at the lowest effective dose minimizes these relative risks, supported by pharmacovigilance data emphasizing early discontinuation upon any adverse signal.

Regulatory History

Development and Initial Approvals

Nimesulide, a sulfonanilide classified as a non-steroidal (NSAID), was first synthesized in the late 1960s by researchers at Pharmaceuticals, with its synthesis process patented in 1974. In 1980, Helsinn Healthcare SA, a pharmaceutical company headquartered in , , acquired the worldwide licensing rights to the compound and initiated comprehensive preclinical and clinical development programs to evaluate its , , and properties. The drug obtained its inaugural marketing authorization in in 1985, launched under brand names including Aulin and Mesulid specifically for short-term management of acute pain and inflammatory conditions such as flares and postoperative discomfort. Approval in followed soon after, reflecting Helsinn's home market and early regulatory acceptance in for targeted acute indications, with broader European rollout occurring progressively into the early . Pre-marketing studies, including animal models and initial human trials submitted to regulatory authorities, demonstrated nimesulide's preferential inhibition of (COX-2) over COX-1, correlating with reduced gastrointestinal mucosal damage relative to non-selective NSAIDs like indomethacin. In models of NSAID-induced enteropathy, nimesulide exhibited less disruption to intestinal and fewer ulcerative lesions than indomethacin at equivalent doses. These findings underscored its potential for improved tolerability in short-duration , influencing early positioning against comparators with higher GI risk profiles.

Emergence of Safety Concerns (1990s–2000s)

Initial reports of nimesulide-associated emerged in the late 1990s, with the first documented cases of acute appearing in 1997. These early signals included sporadic case reports of severe hepatic reactions, prompting increased in . By 1998–1999, alerts for hepatotoxicity were noted in countries like , highlighting patterns of elevated liver enzymes and linked to the drug. In , (ADR) monitoring revealed a disproportionate signal by the late , with spontaneous reports exceeding 100 per 100,000 patient-years—far higher than the typical 1 per 100,000 for other NSAIDs. This included numerous liver-related events, contributing to national concerns over the drug's safety profile and culminating in a marketing authorization suspension in 2002 due to the elevated frequency of . Concurrently, Italian pharmacoepidemiological studies, such as spontaneous reporting analyses from regions like , identified nimesulide as a frequent suspect in drug-induced hepatic reactions during the . The (EMA) initiated an Article 31 referral review in 2002 following Finland's suspension and subsequent actions in other states, including Spain's market withdrawal that year after reports of serious liver damage, including fatalities. Spanish authorities cited pediatric cases among the triggers, leading to restrictions on pediatric formulations across several European countries. Early pharmacoepidemiological data from Italian cohort and case-control studies in the early 2000s estimated the of acute with nimesulide at approximately 3–4 times that of other NSAIDs, though absolute incidence remained low at 1–3 cases per 100,000 users, underscoring the rarity despite the signal strength.

Global Bans and Restrictions (2000s–Present)

Nimesulide has not been approved by the U.S. (FDA) due to safety concerns, rendering it unavailable in the United States. In and , the drug was withdrawn from the market in 2002 following reports of severe . Ireland's Irish Medicines Board suspended marketing authorizations for oral nimesulide products in May 2007 after pharmacovigilance data indicated risks of , including at least seven associated fatalities by that time. and also withdrew nimesulide from their markets amid similar reports. In the , the (EMA) conducted a review triggered by Ireland's suspension and, in 2012, recommended harmonized restrictions: limiting treatment to a maximum of 15 days for adults in second-line use for acute pain or primary , with packs restricted to two-week supplies, and prohibiting use in children and adolescents under 12 years or weighing less than 40 kg. These measures applied to member states where nimesulide remained authorized, such as , , , , and , but did not extend to full withdrawal. Regulatory outcomes have varied internationally without a global consensus. Nimesulide continues to be marketed for adult use in countries including (with pediatric formulations banned in 2011), , and , often as a for short-term pain relief. Decisions reflect differences in local reporting and risk-benefit assessments rather than uniform standards.

Recent Developments (2020s)

In , the Drugs Technical Advisory Board (DTAB) in early 2024 recommended restrictions on nimesulide formulations amid ongoing safety reviews, followed by the (ICMR) advising a ban on all products exceeding 100 mg strength in April 2025, alongside mandatory warnings for risks. DTAB endorsed these ICMR proposals in May 2025, prohibiting oral immediate-release forms above 100 mg while calling for additional data review. In December 2024, the Indian government extended restrictions by banning all veterinary formulations of nimesulide, prompted by experimental evidence of its to vultures, including visceral and renal failure at doses as low as 0.5–1 mg/kg. Despite these measures, the human nimesulide market in permitted regions showed projected growth, with global estimates valuing it at USD 300 million in and forecasting USD 450 million by 2033 at a 5.1% CAGR, attributed to sustained demand for acute relief where alternatives are less favored. Clinical studies from – reinforced nimesulide's in acute and fever, demonstrating faster symptom resolution than ibuprofen-paracetamol combinations and noninferiority to diclofenac-paracetamol, with rates of 13% versus 29% for comparators, including fewer gastrointestinal issues. A 2025 appraisal concluded its incidence aligns with other NSAIDs but features a lower overall serious profile in short-term use, aligning with the European Medicines Agency's 2012 restrictions limiting it to 15-day courses for acute conditions in approved markets.

Controversies and Debates

Hepatotoxicity Debate: Data vs. Regulatory Responses

The hepatotoxicity associated with nimesulide has been quantified in pharmacovigilance databases and registries, where reporting odds ratios (ROR) indicate a disproportionate signal of 4- to 8-fold elevation for liver injury compared to other drugs, though absolute incidence remains low at approximately 1-10 cases per 100,000 users annually. In Italian case-control studies, nimesulide showed an adjusted odds ratio of 7.4 (95% CI 1.9-28.7) for acute liver injury versus non-use of NSAIDs, exceeding risks for ibuprofen or ketoprofen but still classifying the event as rare. These signals are tempered by comparisons to common culprits like amoxicillin-clavulanate, which accounts for higher absolute DILI cases in global registries due to broader exposure, with nimesulide's hepatocellular pattern often milder than antibiotics' cholestatic forms. Establishing causality faces hurdles, including by indication—patients treated for or frequently engage in with other hepatotoxins—and the infrequency of positive rechallenges, which limits definitive attribution under criteria like Roussel Uclaf Causality Assessment Method (RUCAM). reviews noted that many reported cases involved concurrent hepatotoxic agents or underlying , complicating isolation of nimesulide's role, with idiosyncratic metabolism proposed but unproven as the mechanism. Cohort data from databases report only modestly elevated rate ratios (e.g., 1.3 for hepatopathy versus other NSAIDs), suggesting overreporting in spontaneous systems may inflate perceived risks without corresponding population-level mortality spikes. Regulatory responses, such as bans in (2002), (2012), and the (withdrawn 2003), justified restrictions by highlighting clusters of severe outcomes—including fatalities and transplants in rare instances—despite low overall incidence, prioritizing avoidance of preventable harm over probabilistic risk. Pro-ban arguments, as articulated by therapeutic initiative groups, emphasize that even infrequent severe (e.g., 10-20% mortality in jaundiced cases) warrants withdrawal when safer NSAID alternatives exist. In contrast, data-driven perspectives point to sustained high-volume use in —where nimesulide comprises a significant —without documented excess mortality at the level, implying absolute risks may not justify universal . This divergence underscores a tension between signal detection in low-exposure European contexts and real-world safety in broader utilization.

Balancing Benefits and Risks

Nimesulide exhibits a positive risk-benefit profile for short-term treatment of acute , particularly where predominates, due to its rapid and comparable to other non-steroidal anti-inflammatory drugs (NSAIDs) such as and ibuprofen, while presenting lower risks of gastrointestinal complications than many traditional NSAIDs. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) affirmed in 2012 that benefits outweigh risks when restricted to acute for no more than 15 days at the lowest effective dose, as its preferential cyclooxygenase-2 inhibition minimizes upper gastrointestinal events relative to non-selective NSAIDs. Cardiovascular risks, akin to those of other NSAIDs, remain low in short-term use among patients without pre-existing vulnerabilities, with no evidence of elevated short-duration hazards beyond class effects. Although occurs at an estimated incidence of 1 to 5 cases per 100,000 exposed individuals, yielding a high (NNH) that exceeds typical numbers needed to treat (NNT) for meaningful relief (around 3-4 for 50% reduction in acute settings, consistent with NSAID class data), this rarity supports its targeted application over blanket avoidance. Compared to , nimesulide provides superior and efficacy in conditions like postoperative pain or , where paracetamol's weaker inhibition of synthesis limits its impact on inflammatory mediators. Clinical comparisons in pediatric and adult acute pain demonstrate nimesulide's faster normalization of fever and greater reduction in inflammatory markers, positioning it as a more effective option when inflammation drives symptoms, without paracetamol's ceiling effect on analgesia. In underserved populations in low- and middle-income countries, where nimesulide's affordability and availability address gaps in access to specialized analgesics, its economic advantages—such as lower overall treatment costs versus in rheumatic conditions—further justify selective use under monitoring. Empirical data from high-volume markets like , where nimesulide accounts for substantial NSAID prescriptions without corresponding surges in at population levels, reinforce the low absolute risk when usage aligns with short-term guidelines. Reporting rates of severe remain below those in restricted European contexts, attributable to underreporting challenges but also to the drug's infrequent causation of fatal outcomes relative to exposure volume, underscoring that causal attribution requires case-by-case scrutiny rather than aggregate bans. This data-driven perspective prioritizes patient-specific factors, such as absence of hepatic comorbidities, over generalized precautions, aligning with health economic analyses favoring its role in resource-limited scenarios.

Criticisms of Overregulation

Critics of nimesulide's regulatory restrictions contend that bans and severe limitations disproportionately emphasize rare hepatotoxic events while undervaluing the drug's efficacy in acute and its superior gastrointestinal safety profile relative to traditional NSAIDs like or ibuprofen. Pharmacoepidemiological analyses indicate that nimesulide's risk, though elevated in (approximately 2-7 times higher than comparators in some case-control studies), translates to an absolute incidence of 1-10 cases per 100,000 users, comparable to or lower than background rates for other NSAIDs that remain unrestricted globally. This perspective holds that regulators amplify attributable risks from post-marketing —prone to reporting biases and by indication—over empirical benefit data, such as faster onset of analgesia and reduced ulcerogenic potential, leading to decisions detached from causal . Regulatory inconsistencies underscore a caution bias rather than uniform ; for instance, the never approved nimesulide, citing preclinical signals, whereas the in 2012 affirmed its positive benefit-risk for short-term adult use (up to 15 days) after reviewing over 10,000 reports, and permits adult formulations with monitoring, reporting only 129 cases amid billions of doses dispensed since 1990. In , where nimesulide constitutes a significant share of NSAID prescriptions for conditions like and , the absence of population-level surges—despite laxer oversight than in Western markets—suggests overregulation stems from precautionary thresholds prioritizing zero-tolerance for iatrogenic harm over probabilistic harms from untreated pain or alternative therapies. Such variance implies influence from institutional , potentially amplified by selective emphasis on nimesulide amid competitive NSAID markets, rather than rigorous comparative effectiveness trials. Overregulation curtails therapeutic options in resource-limited settings, where nimesulide's affordability (often under $0.05 per dose) and availability provide equitable access to effective analgesia for populations facing higher baseline comorbidities and lower monitoring capacity, potentially shifting reliance to costlier or less tolerable agents. This approach favors paternalistic controls over informed patient choice, ignoring that everyday hepatotoxins like alcohol contribute to far greater burdens—annually causing over 100,000 U.S. hospitalizations from alone, versus isolated nimesulide-linked failures—without analogous prohibitions, highlighting inconsistent application of risk proportionality. Proponents argue that empowering prescribers with guidelines for short-duration use and liver function screening, as practiced in permitted jurisdictions, better balances absolute risks against real-world utility than blanket bans.

Availability and Societal Impact

Brand Names and Formulations

Nimesulide is commercially available under brand names such as Aulin, Mesulid, Nise, and Sulide, with numerous generic equivalents predominant in Asian markets where the drug is permitted. Common formulations include 100 mg tablets for , alongside suppositories at 200 mg doses. Other variants encompass granules for reconstitution into oral suspensions, effervescent tablets, and topical gels for localized application. Pediatric formulations, such as oral suspensions, are available in jurisdictions allowing their use, often at reduced doses. Fixed-dose combinations with are widely produced for synergistic pain relief and effects. Since the original patents expired, generic production has become global among manufacturers in approving regions.

Market Status by Region

In , nimesulide maintains broad availability and high usage for acute , particularly in densely populated markets like and . In , it is accessible over-the-counter for adults, supporting substantial sales volumes despite a 2011 ban on formulations for children under 12 years old. In China, nimesulide is prohibited for children under 12 years and recommended as a second-line option only if other NSAIDs like ibuprofen are ineffective, using the shortest course and minimal effective dose. Market forecasts indicate sustained expansion in the region through 2025, with projections attributing approximately 40-60% of global nimesulide demand to this area due to rising incidences of inflammatory conditions and established prescribing patterns. In Europe, regulatory status varies sharply, with nimesulide authorized under stringent conditions—limited to short-term use (up to 15 days) at low doses for acute pain—in about 10 member states, including , , , , , , , , , and ; it requires a prescription in these jurisdictions. Additional approvals exist in select non-listed states like , , and , but it has been fully withdrawn in numerous others, such as , the , and , reflecting post-EMA reviews prioritizing risks over usage benefits. Overall European consumption remains low compared to , confined to monitored adult prescriptions. In the Americas, nimesulide faces outright prohibitions in key northern markets: it has never received approval from the FDA, is banned in , and withdrawn in due to unresolved liver safety data. Southward, availability persists in , where it is dispensed by prescription for acute conditions in limited durations, contributing to 25% of Latin American amid high demand for affordable analgesics. Conversely, has suspended all presentations following regional risk assessments. Usage patterns here emphasize short-course therapy with mandatory warnings, contrasting unrestricted access elsewhere.

Economic and Access Considerations

Nimesulide's availability as a low-cost generic medication supports affordable pain management in resource-limited environments, with 100 mg tablets in priced at approximately ₹0.5 ($0.006) per dose, far below many branded NSAIDs or alternatives like selective COX-2 inhibitors. This pricing enables broad access for low-income populations in approved markets, where out-of-pocket healthcare expenses predominate and pricier options—such as or in higher doses—can exceed several times the cost per treatment course. The global nimesulide market, valued at around USD 300 million in 2024, is forecasted to expand at a (CAGR) of approximately 5% through 2033, propelled by sustained demand in countries like and , where regulatory approvals persist for short-term human use. Such growth reflects nimesulide's role in addressing unmet needs for cost-effective anti-inflammatory therapy amid rising musculoskeletal disorders in emerging economies. Restrictions on nimesulide, including 's December 2024 prohibition of its veterinary formulations to mitigate toxicity, have negligible effects on human market dynamics, as animal-use volumes represent a minor fraction of overall production. However, broader human-use bans in higher-income regions have sparked debates on equity: the Technical Advisory Board of has highlighted that substitute analgesics are often prohibitively expensive for impoverished patients, potentially amplifying treatment disparities by favoring regulatory caution over empirical risk-benefit assessments in contexts of limited alternatives. Advocates for conditional availability argue that informed prescribing, rather than prohibitions, better balances utility with risks, preserving access where monitoring infrastructure allows.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK547948/
  2. https://go.drugbank.com/drugs/DB04743
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC11126320/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC6345488/
  5. https://www.ema.europa.eu/en/medicines/human/referrals/nimesulide-0
  6. https://pubmed.ncbi.nlm.nih.gov/18333314/
  7. https://www.tandfonline.com/doi/full/10.1185/03007995.2015.1100986
  8. https://www.nature.com/articles/pr200439
  9. https://pubmed.ncbi.nlm.nih.gov/7506193/
  10. https://pubmed.ncbi.nlm.nih.gov/11069726/
  11. https://www.clinexprheumatol.org/article.asp?a=1117
  12. https://www.sciencedirect.com/science/article/abs/pii/S0024320505009598
  13. https://pubmed.ncbi.nlm.nih.gov/11348486/
  14. https://pubmed.ncbi.nlm.nih.gov/12166613/
  15. https://www.sciencedirect.com/science/article/abs/pii/S001429991930069X
  16. https://www.mims.com/malaysia/drug/info/nimesulide?mtype=generic
  17. https://pubmed.ncbi.nlm.nih.gov/9812177/
  18. https://www.openaccessjournals.com/articles/nimesulide-for-painful-osteoarthritis.pdf
  19. https://www.ema.europa.eu/en/documents/referral/nimesulide-article-31-referral-annex-iii_en.pdf-0
  20. https://www.ema.europa.eu/en/documents/referral/nimesulide-article-107-procedures-annex-iii_en.pdf
  21. https://pubmed.ncbi.nlm.nih.gov/7527762/
  22. https://pubmed.ncbi.nlm.nih.gov/7506169/
  23. https://www.ema.europa.eu/en/medicines/human/referrals/nimesulide-1
  24. https://www.drugs.com/medical-answers/nimesulide-3571533/
  25. https://asianjpr.com/HTML_Papers/Asian%2520Journal%2520of%2520Pharmaceutical%2520Research__PID__2021-11-2-11.html
  26. https://www.sciencedirect.com/topics/medicine-and-dentistry/nimesulide
  27. https://www.tuasaude.com/en/nimesulide/
  28. https://www.practo.com/medicine-info/nimesulide-100-mg-tablet-7091
  29. https://pharmevo.biz/wp-content/uploads/2021/03/Nise.pdf
  30. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/92nd%2520DTAB%2520approved%2520minutes.pdf
  31. https://medicaldialogues.in/news/industry/pharma/box-warning-dose-limits-india-set-to-tighten-nimesulide-use-155505
  32. https://www.medindia.net/doctors/drug_information/nimesulide.htm
  33. https://pubmed.ncbi.nlm.nih.gov/12824661/
  34. https://www.bmj.com/content/326/7391/713.1
  35. https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic
  36. https://pubmed.ncbi.nlm.nih.gov/29923044/
  37. https://www.e-lactation.com/en/nimesulide-pr/
  38. https://www.practo.com/medicine-info/nimesulide-201-api
  39. https://europepmc.org/article/med/7506162
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC3964531/
  41. https://pubmed.ncbi.nlm.nih.gov/16092313/
  42. https://www.japi.org/article/japi-73-3-e22
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC2991691/
  44. https://www.semanticscholar.org/paper/A-Randomised%252C-Double-Blind%252C-Clinical-Trial-the-of-Bianchi-Broggini/b88161fb235abeaad17d888196dc53d04b805ad2
  45. https://pubmed.ncbi.nlm.nih.gov/11329096/
  46. https://academic.oup.com/rheumatology/article-pdf/38/suppl_1/33/13068689/38s1033.pdf
  47. https://www.sciencedirect.com/science/article/abs/pii/S014929180285127X
  48. https://www.ijcp.in/Pages/Post_Detail.aspx?wid=20437
  49. https://www.indiapharmaoutlook.com/news/icmr-calls-for-targeted-ban-on-popular-painkiller-over-safety-concerns-nwid-3382.html
  50. https://www.researchgate.net/publication/261727154_Post_marketing_surveillance_study_of_nimesulide_in_Indian_population
  51. https://ammspub.com/index.php/amms/article/view/297
  52. https://scispace.com/pdf/an-open-label-prospective-multicentric-cohort-study-of-156hc9m0.pdf
  53. https://www.sciencedirect.com/science/article/pii/S0011393X98850844
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC1760142/
  55. https://link.springer.com/article/10.2165/00003495-199300461-00070
  56. https://www.researchgate.net/publication/233698400_The_Spectrum_of_Nimesulide-Induced-Hepatotoxicity_An_Overview
  57. https://www.sciencedirect.com/science/article/abs/pii/S1590865809002564
  58. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0209264
  59. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.12938
  60. https://sciensage.info/index.php/JASR/article/download/2143/1534
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC4917796/
  62. https://pubmed.ncbi.nlm.nih.gov/17538762/
  63. https://pubmed.ncbi.nlm.nih.gov/18266822/
  64. https://pubmed.ncbi.nlm.nih.gov/10335911/
  65. https://link.springer.com/article/10.2165/00003495-199300461-00067
  66. https://pubmed.ncbi.nlm.nih.gov/37908194/
  67. https://www.tandfonline.com/doi/abs/10.1080/14740338.2023.2274416
  68. https://www.sciencedirect.com/topics/chemistry/nimesulide
  69. https://biomedicus.gr/nidol-side-effects/
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC1125612/
  71. https://ec.europa.eu/health/documents/community-register/2004/200404267229/anx_7229_en.pdf
  72. https://pubmed.ncbi.nlm.nih.gov/7506187/
  73. https://pubmed.ncbi.nlm.nih.gov/7506198/
  74. https://europepmc.org/article/med/7506186
  75. https://hse.aws.openrepository.com/bitstream/handle/10147/635775/pharmacovigilance%2520and%2520patient%2520safety%2520-%2520lessons%2520from%2520nimesulide%2520ipj%252085.10.2007.pdf?sequence=1&isAllowed=y
  76. https://patents.google.com/patent/CN108653225B/en
  77. https://asianjpr.com/AbstractView.aspx?PID=2021-11-2-11
  78. https://pubmed.ncbi.nlm.nih.gov/9712237/
  79. https://pubmed.ncbi.nlm.nih.gov/10369399/
  80. https://www.pharmaco-vigilance.eu/content/results-european-study-acute-liver-transplant-salt
  81. https://www.sciencedirect.com/science/article/pii/S1590865800803369
  82. https://www.ema.europa.eu/en/documents/referral/nimesulide-article-31-referral-annex-ii_en.pdf
  83. https://journals.lww.com/iphr/fulltext/2004/36040/is_nimesulide_safe_in_a_cardiovascular_compromised.15.aspx
  84. https://www.researchgate.net/publication/298908786_Risk_of_acute_and_serious_liver_injury_associated_to_nimesulide_and_other_NSAIDs_data_from_drug-induced_liver_injury_case-control_study_in_Italy
  85. https://www.ema.europa.eu/en/medicines/human/referrals/nimesulide
  86. https://www.imt.ie/news/sales-of-nimesulide-medications-are-suspended-by-imb-25-05-2007/
  87. https://www.ti.ubc.ca/2008/02/04/nimesulide-must-be-withdrawn-worldwide-due-serious-liver-damage/
  88. https://www.ema.europa.eu/en/documents/referral/questions-answers-review-systemic-medicines-containing-nimesulide_cs.pdf
  89. https://www.news18.com/india/ban-advised-on-nimesulide-doses-above-100-mg-for-adults-black-box-warning-on-all-packs-icmr-report-9309149.html
  90. https://www.pharmabiz.com/NewsDetails.aspx?aid=177771&sid=1
  91. http://www.ingredientssouthasia.com/News/health-ministry-bans-nsaid-drug-nimesulide-for-animal-use
  92. https://www.sciencedirect.com/science/article/abs/pii/S1382668923002260
  93. https://www.verifiedmarketreports.com/product/nimesulide-market/
  94. https://pubmed.ncbi.nlm.nih.gov/38800230/
  95. https://www.japi.org/article/japi-73-7-e1
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC164233/
  97. https://www.ema.europa.eu/en/news/european-medicines-agency-concludes-review-systemic-nimesulide-containing-medicines
  98. https://link.springer.com/article/10.2165/00003495-199300461-00052
  99. https://europepmc.org/article/med/7506181
  100. https://pubmed.ncbi.nlm.nih.gov/10344919/
  101. https://journals.sagepub.com/doi/pdf/10.3233/JRS-130602
  102. https://link.springer.com/article/10.2165/00002018-200326120-00005
  103. https://www.researchgate.net/publication/286235972_Unregulated_Sale_of_Nimesulide_in_India
  104. https://www.chinadaily.com.cn/business/2011-05/21/content_12554267.htm
  105. https://dataintelo.com/report/global-nimesulide-market
  106. https://www.archivemarketresearch.com/reports/nimesulide-346600
  107. https://medicinman.net/2025/05/nimesulide-nice-or-not-nise/
  108. https://www.medindia.net/drug-price/nimesulide/nimesulide-100-mg.htm
  109. https://www.dataintelo.com/report/global-nimesulide-market
  110. https://www.sphericalinsights.com/reports/nimesulide-market
  111. https://save-vultures.org/2025/01/india-issues-gazette-notification-of-veterinary-nimesulide-ban/
  112. https://drugscontrol.org/news-detail.php?newsid=41239
Add your contribution
Related Hubs
User Avatar
No comments yet.